Nuvation Bio Inc(NUVB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:39 PM ET (Korea 10/31 06:39)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.44 | Insider Own | 28.44% | Shs Outstand | 348.8M | Perf Week | 4.16% |
| Market Cap | 1.68B | Forward P/E | - | EPS next Y | 47.81% | Insider Trans | -0.31% | Shs Float | 252.0M | Perf Month | -14.39% |
| Enterprise Value | 1.43B | PEG | - | EPS next Q | -0.12 | Inst Own | 56.16% | Short Float | 25.09% | Perf Quarter | -22.73% |
| Income | -0.15B | P/S | 9.87 | EPS this Y | 32.79% | Inst Trans | 5.85% | Short Ratio | 11.82 | Perf Half Y | 6.01% |
| Sales | 0.17B | P/B | 6.56 | EPS next 5Y | - | ROA | -21.53% | Short Interest | 63.22M | Perf YTD | -46.87% |
| Book/sh | 0.73 | P/C | 2.54 | EPS past 3/5Y | -7.61% -7% | ROE | -47.81% | 52W High | -51.18% ($9.75) | Perf Year | -7.57% |
| Cash/sh | 1.88 | P/FCF | - | Sales past 3/5Y | - | ROIC | -23.07% | 52W Low | 21.43% ($3.92) | Perf 3Y | 376% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 30.89% | Gross Margin | 86.91% | Volatility(W/M) | 4.57% 5.34% | Perf 5Y | -48.09% |
| Dividend TTM | - | EV/Sales | 8.43 | Sales Y/Y TTM | 1083.56% | Oper. Margin | -81% | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.14 | EPS Q/Q | -4.04% | Profit Margin | -88.19% | RSI (14) | 42.24 | Recom | 1.15 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.37 | Sales Q/Q | 555.64% | SMA20 | 0.54% ($4.73) | Beta | 1.71 | Target Price | $13 |
| Payout | - | Debt/Eq | 1.64 | Earnings | 2026/11/4 | SMA50 | -15.51% ($5.63) | Rel Volume | 0.95 | Prev Close | $4.77 |
| Employees | 298 | LT Debt/Eq | 1.56 | EPS/Sales Surpr. | -27.03% 17.24% | SMA200 | -11.81% ($5.4) | Avg Volume(3M) | 5.35M | Price | $4.76 |
| IPO | 2020/8/26 | Option/Short | Yes/Yes | Trades | 10356 | Volume | 5,058,998 | Change | -0.21% |
🧬 This is a U.S. biotech company that develops and commercializes cancer therapeutics. It has commercialized treatments targeting solid tumors, such as lung cancer with specific genetic mutations, while also developing next-generation oncology candidates. Operating under a model that combines expanded prescriptions for its commercial products with its oncology pipeline, it is an oncology-focused biotech firm strengthening its position in the underserved cancer treatment market.
Over the past 1 year, on the lower side
51% below its 1-year high.
Traded about as much as usual. That is 95% of its average volume.
Next earnings report: November 4
5 days to go.
NUVB has a sound balance sheet but weak earning power
Of every $100 in sales, $81.00 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +32.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $987. Peers typically go for $1,217.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -48.1%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
25.1% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #117 of 595 in the industry
Based on market cap of $2B.
STOK#116 Stoke Therapeutics Inc $2B PER - NUVB#117 Nuvation Bio Inc $2B PER - 
REPL#118 Replimune Group Inc $2B PER - 
KLRA#119 Kailera Therapeutics Inc $2B PER - 
NVAX#120 Novavax Inc $2B PER - 
FAQ
What kind of company is NUVB?
NUVB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NUVB?
The market cap of NUVB is approximately $1.7B, ranking 2,194 within its sector.
What is the 52-week high and low for NUVB?
NUVB has recorded a 52-week high of $9.75 and a low of $3.92.
